Eisai Inc Company Profile
What is the competitive landscape for EISAI INC
EISAI INC has eleven approved drugs.
There are sixteen US patents protecting EISAI INC drugs.
Summary for Eisai Inc
| US Patents: | 16 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 11 |
Drugs and US Patents for Eisai Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | 11,186,547*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | 10,702,529 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eisai Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eisai Inc | LUSEDRA | fospropofol disodium | SOLUTION;INTRAVENOUS | 022244-001 | Dec 12, 2008 | 6,204,257 | ⤷ Start Trial |
| Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-001 | Nov 25, 1996 | 6,245,911 | ⤷ Start Trial |
| Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 6,245,911 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EISAI INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 4 mg and 10 mg | ➤ Subscribe | 2019-02-13 |
| ➤ Subscribe | Tablets | 100 mg, 200 mg and 400 mg | ➤ Subscribe | 2012-11-14 |
| ➤ Subscribe | Orally Disintegrating Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-06-30 |
| ➤ Subscribe | Tablets | 23 mg | ➤ Subscribe | 2013-07-09 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2014-06-16 |
International Patents for Eisai Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6306235 | ⤷ Start Trial |
| South Korea | 100589032 | ⤷ Start Trial |
| Ukraine | 108510 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eisai Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1087960 | 2011C/028 | Belgium | ⤷ Start Trial | PRODUCT NAME: ERIBULIN; AUTHORISATION NUMBER AND DATE: EU/1/11/678/001 20110317 |
| 1698623 | 261 5023-2015 | Slovakia | ⤷ Start Trial | PRODUCT NAME: LENVATINIB MESYLAT; REGISTRATION NO/DATE: EU/1/15/1002/001 - EU/1/15/1002/002 20150601 |
| 0296560 | SPC/GB97/023 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
